Centessa Pharmaceuticals
Dirigeants
Voir l'organigramme avec ses 19 principaux dirigeants
Biographies les plus recherchées chez Centessa Pharmaceuticals
- Saurabh Saha, Chief Executive Officer and Director
- Francesco De Rubertis, Chairman of The Board
- Mary Hedley, Director
Changements de dirigeants chez Centessa Pharmaceuticals
- Ellie Im, a rejoint l'entreprise comme Senior Vice President of Clinical Development, Oncology (publié le 3 octobre 2023).
- April Dovholuk, a rejoint l'entreprise comme Senior Vice President of Development Operations (publié le 3 octobre 2023).
Créer une alerte
pour suivre les mouvements de dirigeants chez Centessa Pharmaceuticals.
Pharmacie
Centessa Pharmaceuticals a 1 863 concurrents dont Pfizer (Etats—Unis), Sanofi (France) et Johnson & Johnson (Etats—Unis).
Actualités en fusion/acquisition en Pharmacie.
- AstraZeneca has announced the acquisition of Fusion Pharma (publié le 23 mars 2024).
- AstraZeneca has announced the acquisition of Amolyt Pharma (publié le 19 mars 2024).
- Frontier Medicines vient d'annoncer une levée de fonds de 80 millions de dollars. (publié le 27 février 2024).
Contacts en Pharmacie
Actualités
Derniers communiqués de presse par Centessa Pharmaceuticals
- Centessa Pharmaceuticals Announces Addition of Harris L. Rotman, PhD, as Senior Vice President of Regulatory Affairs | Centessa Pharmaceuticals
- Centessa Pharmaceuticals Announces Appointment of Dr. Mathias Hukkelhoven to its Board of Directors | Centessa Pharmaceuticals
- Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences | Centessa Pharmaceuticals
- Centessa Pharmaceuticals Announces Poster Presentation of First Preclinical Data for LockBody® Program at 2022 ASCO Annual Meeting | Centessa Pharmaceuticals
- Centessa Pharmaceuticals Makes Strategic Decision to Discontinue Clinical Development of Lixivaptan for Autosomal Dominant Polycystic Kidney Disease (ADPKD) | Centessa Pharmaceuticals
- Centessa Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Business Updates | Centessa Pharmaceuticals
- Centessa Pharmaceuticals Doses First Subject in Global Phase 3 ACTION Study of Lixivaptan in Autosomal Dominant Polycystic Kidney Disease | Centessa Pharmaceuticals
- Centessa Pharmaceuticals Reports Fourth Quarter and 2021 Financial Results and Provides Business Update | Centessa Pharmaceuticals
- Centessa Pharmaceuticals Expands Management Team and Adds to Extensive Development Expertise | Centessa Pharmaceuticals
- Centessa Pharmaceuticals to Present at the Guggenheim Genomic Medicines & Rare Disease Day | Centessa Pharmaceuticals
- Voir plus de communiqués de presse Close
Réseaux sociaux à propos de Centessa Pharmaceuticals
- Centessa Pharmaceuticals sur Wikipédia, Google News & Yahoo Finance en 1-click
- Centessa Pharmaceuticals sur LinkedIn, Twitter & YouTube en 1-click
